Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB₁ activation

Christopher P. Stanley, William H. Hind, Cristina Tufarelli, and Saoirse E. O’Sullivan*

School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK

Received 4 September 2014; revised 20 May 2015; accepted 12 June 2015; online publish-ahead-of-print 19 June 2015

Time for primary review: 41 days

Aims

The protective effects of cannabidiol (CBD) have been widely shown in preclinical models and have translated into medicines for the treatment of multiple sclerosis and epilepsy. However, the direct vascular effects of CBD in humans are unknown.

Methods and results

Using wire myography, the vascular effects of CBD were assessed in human mesenteric arteries, and the mechanisms of action probed pharmacologically. CBD caused acute, non-recoverable vasorelaxation of human mesenteric arteries with an Rₘₐₓ of ≏ 40%. This was inhibited by cannabinoid receptor 1 (CB₁) receptor antagonists, desensitization of transient receptor potential channels using capsaicin, removal of the endothelium, and inhibition of potassium efflux. There was no role for cannabinoid receptor-2 (CB₂) receptor, peroxisome proliferator activated receptor (PPAR)γ, the novel endothelial cannabinoid receptor (CBe), or cyclooxygenase. CBD-induced vasorelaxation was blunted in males, and in patients with type 2 diabetes or hypercholesterolemia. In HAECs, CBD significantly reduced phosphorylated JNK, NFκB, p70s6K and STAT5, and significantly increased phosphorylated CREB, ERK1/2, and Akt levels. CBD also increased phosphorylated eNOS (ser1177), which was correlated with increased levels of ERK1/2 and Akt levels. CB₁ receptor antagonism prevented the increase in eNOS phosphorylation.

Conclusion

This study shows, for the first time, that CBD causes vasorelaxation of human mesenteric arteries via activation of CB₁ and TRP channels, and is endothelium- and nitric oxide-dependent.

Keywords

Vasorelaxation • Human • Cannabidiol • Cannabinoid • Endothelium

1. Introduction

Numerous studies have shown that endogenous, synthetic, and plant-derived cannabinoids cause vasorelaxation of a range of animal and human arterial beds. The extent of cannabinoid-induced vasorelaxation and the mechanisms involved often differs between the cannabinoid compound studied, the arterial bed used, and the species employed. These mechanisms include activation of cannabinoid receptor one (CB₁), cannabinoid receptor two (CB₂), transient receptor potential vanilloid one (TRPV1), peroxisome proliferator activated receptor gamma (PPARγ), and an as yet unidentified endothelial-bound cannabinoid receptor (CBe). Vasorelaxant mediators implicated in cannabinoid-induced vasorelaxation include nitric oxide production, prostaglandin production, metabolite production, and ion channel modulation, some of which have been shown to be coupled to receptor activation.

Cannabidiol (CBD) is a naturally occurring molecule found in the plant Cannabis sativa. Unlike the related molecule Δ⁹-tetrahydrocannabinol (THC), it does not activate CB₁ receptors in the brain, and is devoid of the psychotrophic actions of THC. Indeed, CBD may antagonize the psychoses associated with cannabis abuse. Other receptor sites implicated in the actions of CBD include the orphan G-protein-coupled receptor GPR55, the putative endothelial cannabinoid receptor (CBe), the transient receptor potential vanilloid 1 (TRPV1) receptor, α₁-adrenoceptors, μ opioid receptors and 5-HT₁A receptors. A CBD/THC combination (1 : 1 ratio, Sativex/Nabiximols) is currently licensed internationally in more than 20 countries for the treatment of spasticity in multiple sclerosis, and as an as yet unlicensed CBD alone...
product (Epidiolex) has entered an expanded access programme in children with intractable epilepsies. CBD has also received orphan designation status in treating newborn children with neonatal hypoxic-ischaemic encephalopathy.

In addition to the licensed indications, preclinical evidence suggests CBD has therapeutic potential in diseases associated with inflammation, oxidative stress, gastrointestinal disturbances, neurodegeneration, cancer, diabetes, and nociception.6–10 In the cardiovascular system, CBD treatment in vivo reduces endothelial and cardiac dysfunction in cardiomyopathy associated with diabetes.11,12 CBD also reduces vascular inflammation associated with endotoxin shock,13 has a protective role in diabetic retinopathy,14 and is cardioprotective after coronary artery ligation.15 Furthermore, CBD reduces infarct size and increases cerebral blood flow in a mouse model of stroke when delivered either pre- or post-ischaemia through activation of 5-HT1A receptors.16–19

Unlike other cannabinoids, the direct vascular effects of CBD have not been fully investigated in either animal or human studies.1 Juri et al.20 showed that CBD (10 μmol/L) had no effect on vascular tone in the perfused mesenteric arterial bed of mice. However, Offer-taler et al.21 reported that CBD caused a concentration-dependent near maximal vasorelaxation of isolated rat mesenteric arteries, but no mechanisms of action were probed. In the rat isolated aorta, we showed that CBD causes a time-dependant vasorelaxant response that was inhibited by antagonism of the PPARγ receptor and inhibition of superoxide dismutase.22

In light of the increasing evidence that CBD has beneficial effects on the cardiovascular system, and since the vascular effects of CBD remain to be characterized in human vasculature, the aim of the present study was to establish the acute vascular effects of CBD in human arteries and to underpin the pharmacology behind any potential response.

2. Methods

Ethical approval was granted by the Derbyshire Research Ethics Committee and Derbyshire Hospitals Trust Research and Development to take mesenteric tissue from patients (27 males, 10 females) undergoing colorectal surgery. Informed consent was gained in accordance with the Declaration of Helsinki. Mesenteric arteries have been extensively used to characterize the pharmacological effects of cannabinoids.3 Excised mesenteric tissue was placed in physiological saline solution (PSS) and transported back to the lab. Arteries (701 ± 42 μm diameter, mean ± SEM) were dissected from mesenteric tissue, cleaned of any adherent fatty and connective tissue and cut into 2 mm segments. Artery segments were either used fresh or to after overnight storage in PSS at 4°C. Overnight storage had no significant effect on the contractile or relaxation responses of mesenteric arteries (see Supplementary material online, Figure S1). Artery segments were mounted on tungsten wires on a Mulvany-Halpern myograph (Danish Myo Technology, Denmark) at 37°C in PSS solution and gassed with 5% CO2 in O2. Tension was measured using isometric force displacement transducers and recorded using Chart 5 Pro (ADinstruments, Oxfordshire, UK). Using normalization software, arteries were set to an internal diameter producing >5 mN was achieved, cumulative concentration–response curves were constructed to CBD. CBD was added in 5-min intervals with measurements taken in the final minute of each concentration addition and expressed as percentage relaxation of pre-imposed tone. Responses were compared with ethanol-treated vehicle controls carried out in adjacent arterial segments from the same patient. To characterize mechanisms underpinning CBD-induced vasorelaxation, all interventions were compared with a CBD control—response carried out in adjacent arteries from the same patient. In some experiments, the endothelium was removed by abrasion using a human hair. A role for the involvement of nitric oxide was investigated using NG-nitro-ω-arginine methyl ester (−NAME, 300 μmol/L, present throughout). A role for cyclooxygenase (COX) was assessed using indomethacin (10 μmol/L, present throughout). A potential role for potassium channel hyperpolarization was investigated by carrying out concentration–response curves to CBD in arteries contracted using KPSS to inhibit potassium efflux. Potential cannabinoid receptor involvement in CBD-induced vasorelaxation was assessed with CB1 antagonist AM251, 100 μmol/L or LY320135 1 μmol/L, CB2 receptor antagonist AM630 (100 μmol/L), or proposed endothelial cannabinoid receptor (CBα, O1918, 10 μmol/L). Desensitization of sensory nerves was achieved via incubation (1 h) with capsaicin (10 μmol/L) followed by three washouts in PSS. In experiments to establish the potential location of the CB1 receptor, the effects of AM251 in endothelial-denuded arteries were compared with arteries that were endothelial denuded only, arteries treated with AM251 only and CBD control arteries. In each of these protocols, there was no significant difference in the level of contraction immediately before the CBD concentration response curve.

2.2 Cell culture

Human aortic endothelial cells (PromoCell, Germany, passage 4) were grown in PromoCell Endothelial Cell Growth medium to confluence on 6-well plates and treated for 10 min with increasing concentrations of CBD, after which time the medium was removed and the cells collected in cell lysis buffer (RIPA buffer, SigmaAldrich) with phosphatase and protease inhibitors (Roche). Some experiments were performed in the presence of AM251 or capsaepine. The protein concentration of the cell lysate was measured using a BCA assay (BCA-1KT, SigmaAldrich). The levels of phosporylated ERK/MAP kinase 1/2 (Thr185/Tyr187), Akt (Ser473), STAT3 (Ser727), JNK (Thr183/Tyr185), p70 S6 kinase (Thr412), NFkB (Ser536), eNOS phosphorylation was measured in cell lysates using the LumineX® xMAP® technology using a commercially available panel (MilliplexTM, 48-680MAG, Merck Millipore), and normalized to total protein content. eNOS phosphorylation was measured using a PathScan Phospho-eNOS (ser1177) sandwich ELISA according to the manufacturer’s instructions (Cell Signaling Technology, USA), and was normalized to total protein content.

2.3 Reverse transcription-polymerase chain reaction

The presence of target sites of action was investigated at the mRNA level using reverse transcription followed by polymerase chain reaction (RT-PCR) under control conditions, and in the presence of a high glucose (25 mM) or high insulin (500 mM) medium for 96 h. Human astrocytes (HA) were used as a positive control known to express all the target sites of action of interest.23 Total RNA was extracted from HA and HAECs using Allprep DNA/RNA kit with column DNAel treatment (Qiagen, Germany). Reverse transcription with and without reverse transcriptase was performed in 30 μl final volume using 3 μg of total RNA and random primers with the High Capacity cDNA Reverse Transcription Kit (Life Technologies, UK) according to the manufacturer’s instructions. PCRs were carried out in a final volume of 25 μl with ZymoTaq (ZymoResearch, USA) using 2 μl of reverse transcription product as the template. Primer pairs used to amplify 128 bp of the control housekeeping gene...
Hypoxanthine-guanine PhosphoRibosylTransferase (HPRT) were from ref. 24; those for 99 bp PPARα and 87 bp PPARγ were from ref. 25; those for 303 bp CB1R and 365 bp CB2R were from ref. 26; those for 511 bp TRPV1 were from ref. 27; and finally the 380 bp calcitonin gene-related peptide (CGRP) receptor (CGRPR) cDNA fragment was amplified using the primers reported in ref. 28. After 5 min at 95°C, PCRs were performed for 40 cycles except those for CB2R that was carried out for 50 cycles. The cycles included 30 s at 95°C, 30 s at the annealing temperature that was optimal for each primer pair (56°C for CB1R and CB2R; 60°C for all others) and a final extension step of 30 s at 72°C. Amplification products were separated by gel electrophoresis through ethidium bromide stained 2% agarose (CB1R, CB2R, TRPV1, CGRPR) and 3% NuSieve 3:1 (PPARα, PPARγ and HPRT) and visualized using a Biorad Chemidoc.

2.4 Statistical analysis

Graphs represent mean percentage relaxations, with error bars representing the standard error of the mean (SEM) fit to non-linear Regression (Curve Fit) (Prism Version 6; GraphPad Software, CA, USA). n represents the number of arteries from patients. Comparisons between intervention and control artery segments from the same patient were made using Student’s t-test. In experiments to assess the location of the CB1 receptor, comparisons were made between artery segments from the same patient using one way analysis of variance (ANOVA) with Dunnett’s post-hoc analysis. Significance was determined as P < 0.05.

2.5 Chemicals

All salts, L-NAME, indomethacin and bradykinin were supplied by Sigma Chemical Co. (Poole, UK). AM251, LY 320135, AM630, and capsaicin were purchased from Tocris (Bristol, UK). CBD was a kind gift from GW Chemical Co. (Poole, UK). AM251, LY 320135, AM630, and capsaicin were dissolved in ethanol at 10 mM with further dilutions made in distilled water. AM251, LY320135, and AM630 were dissolved in DMSO at 10 mmol/L with further dilutions made in distilled water.

3. Results

Thirty-four patients (24 males and 10 females) were recruited for this study. Twenty-seven had cancer and 7 had inflammatory bowel disorder. A summary of patient characteristics, medical history, and medications is presented in Table 1.

CBD caused vasorelaxation of pre-constricted human mesenteric arteries with an Rmax of around 40% vasorelaxation (Rmax P < 0.0001 compared with vehicle control, n = 12, Figure 1A and C, Table 2). For comparison, the vasorelaxant response to 10 μmol/L bradykinin (83 ± 3 (mean ± SEM) % relaxation) in the same patients is represented in Figure 1C. When added to un-contracted arteries, CBD had no effect on baseline tone (n = 6, representative raw trace shown in Figure 1A). In time-dependent experiments, a single concentration of 10 μmol/L CBD caused an initial vasorelaxation of 57 ± 4% relaxation at 15 min, developing to 78 ± 7% at 120 min (P < 0.001, n = 6, Figure 1D).

Removal of the endothelium significantly reduced the potency (EC50) of CBD (P < 0.0001, Figure 2A, Table 2). The maximum vasorelaxation response to 10 μmol/L CBD also correlated positively with the endothelium-dependent bradykinin response in patients (r = 0.394, P = 0.0158, Figure 2B). Inhibition of COX activity using indomethacin had no effect on the CBD-induced vasorelaxation (n = 6, Figure 2C). In arteries

### Table 1 Patient characteristics, diagnosis, and medications

| Characteristic | Range | Mean ± SEM |
|---------------|-------|------------|
| Ethnicity     | 34 UK white |           |
| Male          | 24    |            |
| Female        | 10    |            |
| Age           | 36–82 | 65 ± 2.1   |
| Weight (kg)   | 52–126| 76 ± 3     |
| BMI (kg/m²)   | 17.5–36.4| 27.1 ± 0.7|
| Vessel size (μm) | 346–1372 | 701 ± 42   |
| Bradykinin response (% relaxation) | 70–109 | 85 ± 1.4   |
| Smoking habits |       |            |
| Non-smokers   | 28    |            |
| 0–10 CPD      | 3     |            |
| 10–20 CPD     | 3     |            |
| Drinking habits |      |            |
| < 10 units p/w | 23    |            |
| 10–20 units p/w | 7     |            |
| > 20 units p/w | 4     |            |
| Operation     |       |            |
| Right hemicolec tomy | 10    |            |
| Left hemicolec tomy | 7     |            |
| Sigmoid colec tomy | 5     |            |
| Anterior resection | 10    |            |
| Abdominoperineal resection | 1     |            |
| Total colec tomy | 1     |            |
| Reason for surgery |     |            |
| Cancer        | 27    |            |
| Inflammatory bowel disorder | 7     |            |
| Dukes Staging |       |            |
| Dukes A       | 10    |            |
| Dukes B       | 9     |            |
| Dukes C       | 8     |            |
| Dukes D       | 0     |            |
| Systolic blood pressure (mm/Hg) | 110–188 | 143 ± 3    |
| Diastolic blood pressure (mm/Hg) | 62–101 | 82 ± 1     |
| Diabetic      | 10    |            |
| Heart disease | 9     |            |
| Heart failure | 0     |            |
| Hypercholesterolemia | 15    |            |
| Hypertensive  | 16    |            |
| α1-adrenoceptor antagonist | 3     |            |
| ACE inhibitors | 7     |            |
| AT1 receptor antagonists | 2     |            |
| Beta-blockers | 6     |            |
| Calcium-channel blocker | 3     |            |
| Digoxin       | 2     |            |
| Diuretics     | 3     |            |
| GTN           | 3     |            |
| Hypoglycaemic medication | 6     |            |
| NSaid medication | 14    |            |
| Statin        | 14    |            |
| Thiazolidinedione | 1     |            |

**Referenced artwork:**
- Figure 1A, C
- Figure 2A, B, D
- Table 2
contracted using high potassium physiological salt solution (KPSS). CBD-induced vasorelaxation was significantly inhibited ($R_{\text{max}}$ $P < 0.001, n = 5$ Figure 2D). Although incubation with L-NAME did not significantly affect the concentration–response curve to CBD ($R_{\text{max}}$ $P$, Figure 2B, Table 2), a trend for a reduction in the vasorelaxant effect of CBD was seen. Therefore, in cultured endothelial cells, we tested whether CBD affects eNOS activation and found that CBD (10 $\mu$mol/L, 10 min) significantly increased eNOS phosphorylation at ser1177 ($P$, $0.05, n = 9$, Figure 2F). Neither endothelium-denudation, L-NAME, or KPSS contraction affected control vasorelaxant responses (see Supplementary material online, Figure S2).

Antagonism of the CB$_1$ receptor using AM251 (100 nmol/L) significantly inhibited CBD-induced vasorelaxation ($R_{\text{max}}$ $P < 0.001, n = 9$, Figure 3A, Table 2). To confirm this result, a second, structurally different antagonist LY320135 was used, which also significantly reduced the maximal response to CBD (CBD $R_{\text{max}}$ 45 $\pm$ 3.5; CBD&LY $R_{\text{max}}$ 30 $\pm$ 5.4, $P < 0.05$, Table 2). Antagonism of the CB$_2$ receptor using AM630 (100 nmol/L) had no effect on CBD-induced vasorelaxation (n = 8, Figure 3C). Desensitization of TRP channels using capsaicin (10 $\mu$mol/L) reduced CBD-induced vasorelaxation (P < 0.0001, n = 7, Figure 3B). Antagonism of the proposed CB$_3$ receptor using O-1918 (10 $\mu$mol/L, n = 7, Figure 3D) had no effect on the CBD-induced vasorelaxation. In the presence of the PPARgamma antagonist GW9662, neither the immediate nor the time-dependent vasorelaxation was inhibited (n = 5, representative raw trace shown in Figure 1B).

In experiments to determine the location of the CB$_1$ receptor, AM251, and endothelial denudation were compared in combination and individually against control CBD responses, obtained from adjacent segments of artery from the same patients (n = 6, Figure 4A). AM251 alone, and AM251 plus denudation, resulted in a significant reduction in the maximal response ($R_{\text{max}}$) to CBD to similar extent ($P < 0.05$, Figure 4C). However, when looking at the entire concentration response curve to CBD (AUC values), the combination of AM251 and endothelial denudation had a more significant ($P$, 0.01) reduction than AM251 alone ($P < 0.05$, Figure 4B).

Across the 37 patients tested, considerable variability of control responses to CBD was observed among patients (the maximal response to CBD ranged from 2 to 75% relaxation), so post hoc analysis was carried out to establish any relationships between CBD responses and patient characteristics (see Supplementary material online, Table S1 and Figures 3 and 4). CBD responses were slightly reduced in males compared with females ($P = 0.0166$), but were not affected by age, BMI, or smoking status. Looking at concurrent diseases, CBD responses were reduced in patients with type-2 diabetes ($P < 0.0001$).
Table 2 The maximal vasorelaxant responses and potency of CBD in human mesenteric arteries

| Vehicle       | CBD          | n |
|--------------|--------------|---|
| R_{max}      | 10.2 ± 3.5   | 12 |
| EC_{50}      | -4.98 ± 0.87 |    |
| Control CBD  | -5.14 ± 0.21 |    |
| Minus endothelium | 51.6 ± 2.8 | 5 |
| L-NAME       | 51.4 ± 4.9   | 5 |
| Indomethacin | 50.4 ± 4.0   | 6 |
| KPSS contracted | 49.7 ± 5.8 | 5 |
| AM251        | 53.9 ± 3.7   | 9 |
| LY320135     | 45.0 ± 3.5   | 5 |
| AM630        | 58.7 ± 3.9   | 8 |
| Capsaicin pre-treatment | 47.7 ± 2.4 | 7 |
| O-1918       | 51.8 ± 2.8   | 7 |

Table 2: The maximal vasorelaxant responses and potency of CBD in human mesenteric arteries. 

Sigma9oidal concentration-response curves to CBD were fitted using Prism and R_{max} and EC_{50} values were compared by Student's t test (with Welch's correction for groups with unequal standard deviations). 

4. Discussion

This is the first study to show that CBD induces vasorelaxation in human mesenteric arteries which is dependent on CB₁ and TRPV1 receptor activation, the endothelium, nitric oxide, and potassium channel modulation. CBD-induced vasorelaxation is reduced in males, and in patients with type-2 diabetes, hypercholesterolemia and in patients taking statins, beta blockers and hypoglycaemic medication.

We found that CBD causes half-maximal vasorelaxation with a pEC_{50} in the mid-micromolar range. Similar findings have been reported in the rat mesenteric artery, where CBD causes vasorelaxation with mid-micromolar potency, however, in the rat model CBD caused near maximal vasorelaxation. This might suggest that the efficacy of CBD is reduced in human vasculature. However, it should be noted that the present studies were performed in older patients with a variety of comorbidities and medications, while animal studies are performed in same gender, young homogenous populations. As we observed that some diseases and medications were associated with lower responses to CBD, this might account for the apparent reduced efficacy in humans. As no mechanistic studies with CBD in animal tissue have yet been reported, we cannot compare the mechanisms of action established in the present study with that from animal tissue.

The endothelium mediates vasorelaxation of the CBD analogue Abn-CBD, and this vasorelaxation is associated with activation of the CB₁ receptor which is antagonized using O-1918. We also found that removal of the endothelium reduced responses to CBD and that CBD vasorelaxant responses correlated with bradykinin responses, indicating an endothelial site of action for CBD. However, in the presence of O-1918, CBD-induced vasorelaxation is unaltered, suggesting that the endothelial component is not CB₁. We also found that CBD responses tended to be reduced in the presence of L-NAME. To explore this further, we found that CBD significantly increased the phosphorylation of eNOS in human aortic endothelial cells, suggesting that production of NO at least partially underlies the endothelium-dependent vasorelaxant effect of CBD. The present study also reports that CBD-induced vasorelaxation is significantly inhibited in arteries contracted using high potassium solution, as has been shown for the vascular response to many cannabinoids. This suggests a predominant mechanism of CBD-induced vasorelaxation is activation of potassium channels and subsequent hyperpolarization. Given the extent of inhibition caused by KPSS, it is unlikely that potassium channel involvement is exclusive to the endothelium.

Activation of CB₁ and CB₂ receptor has been implicated in cannabinoid-induced vasorelaxation. Since human vascular smooth muscle and endothelial cells express these receptors, and CBD has been shown to bind to these receptors at low micromolar concentrations, they were considered as potential mechanisms underpinning CBD-induced vasorelaxation. Antagonism of the CB₁ receptor in two separate experiments using AM251 (see Figures 3 and 4) revealed inhibition of CBD-induced vasorelaxation, suggesting CB₁ is a target for CBD. A second structurally different antagonist, LY320135, was also found to inhibit the vasorelaxant response to CBD, further implicating CB₁ receptor activation. Other authors have suggested that CBD may...
have indirect actions at CB1 through inhibition of FAAH activity or transport,\textsuperscript{30} rather than direct activation. However, we have previously shown that CBD is a more efficacious vasorelaxant of human mesenteric arteries than anandamide\textsuperscript{38} and that the mechanisms of action of CBD presented in the present study are different to those revealed recently in our laboratory for the endocannabinoid 2-AG.\textsuperscript{39} Despite this, CBD has low affinity for CB1 receptors so the possibility still exists that some of the actions of CBD are through inhibition of endocannabinoid degradation. Antagonism of the CB2 receptor using AM630 did not inhibit CBD-induced vasorelaxation. This was unsurprising as CB2 receptor activation is not commonly found to underpin the vasorelaxant effects of cannabinoids.\textsuperscript{1}

The CB1 receptor is expressed in both human endothelial cells and vascular smooth muscle cells.\textsuperscript{32,35} In order to establish the location of the CB1 receptor mediated the vasorelaxant response to CBD, we compared responses with CBD in arteries both denuded and treated with AM251 to either intervention alone. Although the reduction in the maximal response to CBD was similar in arteries treated with AM251 alone as to both interventions, the entire response to CBD (represented by the AUC data) was more significantly reduced by the combination of both interventions. We take this data to suggest that CBD acts at CB1 located on both the endothelium and smooth muscle.

CBD\textsubscript{1} activation has been shown to be coupled to the release of NO.\textsuperscript{40} In support of this, we found that in human endothelial cells, CBD increased the phosphorylation of eNOS at ser1177. Control responses to CBD and interventions were carried out in adjacent segments of mesenteric artery from the same patient. $R_{\text{max}}$ and EC\textsubscript{50} values were compared by paired Students t-test, *$P$ < 0.05, **$P$ < 0.01, ***$P$ < 0.001, ****$P$ < 0.0001.

CB\textsubscript{1} activation has been shown to be coupled to the release of NO.\textsuperscript{40} In support of this, we found that in human endothelial cells, CBD increased the phosphorylation of eNOS, the mRNA of CB1R was present, and in the presence of AM251, the increase in eNOS phosphorylation by CBD was no longer significant.

Plant-derived cannabinoids are good activators of the TRPV channel family\textsuperscript{41} and CBD induces cancer cell apoptosis\textsuperscript{42} and anti-hyperalgesic responses to inflammatory pain\textsuperscript{43,44} through activation of TRPV channels. In the present study, desensitization of TRP channels by exposure to the TRPV1 agonist capsaicin inhibited CBD-induced vasorelaxation, implicating TRP activation. In the rat mesenteric artery, vasorelaxation to two chemically closely related cannabinoids, THC and cannabinol, are also inhibited by capsaicin pre-treatment, acting via the release of the vasoactive neuropeptide calcitonin gene-related peptide (CGRP).\textsuperscript{45} Recent work showed that CGRP vasorelaxant responses in human arteries are endothelium-independent,\textsuperscript{46} suggesting the residual relaxation to CBD observed after endothelium-denudation is probably the TRP component of this response. However, we also observed that the increase in ERK caused by CBD in human endothelial cells was inhibited by TRPV1 antagonism, indicating that TRP activation on both the endothelium and smooth muscle cells could mediate some of the effects of CBD.
**Figure 3** Target sites of action for CBD-induced relaxation of human mesenteric arteries. CBD-induced vasorelaxation of human mesenteric arteries after 10 min incubation (pre-contraction) with the CB₁ antagonist AM251 (100 nmol/L, n = 9, A), the CB₂ antagonist AM630 (100 nmol/L, n = 8, C), the proposed endothelial receptor (CBₑ) antagonist O-1918 (10 μmol/L, n = 7, D), or after desensitization of sensory nerves by 1 h pre-treatment with the TRPV1 agonist capsaicin (10 μmol/L, n = 7, B). Control responses to CBD and interventions were carried out in adjacent segments of mesenteric artery from the same patient. Rₘₐₓ and EC₅₀ values were compared by paired Students t-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

**Figure 4** Location of the CB₁ receptor. Mean CBD-induced vasorelaxation in control arteries, endothelial denuded arteries, in arteries incubated with the CB₁ antagonist AM251 or in arteries that are endothelial denuded and incubated with AM251 (A) and the corresponding Rₘₐₓ (B) and AUC (C) values within each patient (n = 6). Control responses to CBD and the three interventions were carried out in adjacent segments of mesenteric artery from the same patient. Data were compared using one way analysis of variance (ANOVA) with Dunnett’s post hoc analysis comparing against the CBD control data. *P < 0.05, **P < 0.01.
In the rat aortae, CBD causes time-dependent vasorelaxation that can be inhibited by PPARγ antagonism. In human small mesenteric arteries, we found that CBD-induced vasorelaxation also gradually increases with time, but this effect was not inhibited by PPARγ antagonism. However, we previously observed in rats that PPARγ-mediated time-dependent vasorelaxant responses to cannabinoids were only observed in conduit arteries such as the superior mesenteric artery and aorta, but not in third-order mesenteric arteries. Thus the lack of PPARγ-mediated vasorelaxation seen to CBD may be due to the size of the arteries in the present study. An interesting observation was that the vasorelaxant response to CBD was non-recoverable, persisting up to 2 h post-administration. This is in contrast to our previous observations with THC where tone recovered. However, the mechanisms of action (CB1, NO, and the endothelium) of CBD reported in the present study are very different to that reported for THC.

**Figure 5** Signal transduction by CBD in human endothelial cells. Levels of phosphorylated CREB (A), JNK (B), NFκB (C), p38 (D), ERK/MAP kinase 1/2 (E), Akt (F), p70 S6 kinase (G), STAT3 (H), and STAT5A/B (I) were measured in human aortic endothelial cell lysates after 10 min treatment with increasing concentrations of CBD using the Luminex® xMAP® technology and normalized to total protein content. MFI, median fluorescent intensity. Data are presented as mean ± SEM (n = 6) and were analysed by ANOVA with Dunnett’s post-hoc analysis against the vehicle control response. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Human endothelial cell-based studies showed that CBD causes a range of intracellular signalling pathways to be altered at concentrations from 100 nM, but not in a classical concentration-dependent manner. This non-classical concentration–response, particularly for ERK and Akt activation, may be a result of activation of multiple targets by CBD. Indeed the ERK activation appeared to be inhibited by antagonists of both CB1 and TRPV1. Bell-shaped response curves to CBD are also commonly observed.49,50 The observed phosphorylation of ERK and Akt is consistent with known CB1-mediated signal transduction, and CB1-mediated activation of ERK has been observed in human umbilical vein endothelial cells.35 Indeed, we found that CB1 antagonism prevented this increase in ERK. Cannabinoid activation of both MAPK and Akt in the vasculature has also been suggested to be via non-CB1/CB2 mechanisms such as CBe.51,52 However, given our response to CBD was not antagonized by O-1918, it is unlikely that CBD acts through this site. Vasorelaxation to many compounds is mediated by activation of ERK and Akt, thus the CBD-induced increased in both ERK and Akt and therefore both may represent the intracellular signalling mechanisms underpinning the vasorelaxant effects of CBD, as suggested by the positive correlation with eNOS phosphorylation and the inhibition of eNOS phosphorylation by AM251.

CBD also significantly decreased the level of phosphorylated JNK and NFkB, key pro-inflammatory pathways, in human endothelial cells. This is consistent with previous studies showing CBD can attenuate the increase in JNK and NFkB caused by hepatic ischemia/reperfusion injury,53 diabetic cardiomyopathy,11 and hyperglycaemia.12 Our data suggest that reductions in these inflammatory pathways in endothelial cells may underpin some of the protective effects of CBD observed in the vasculature.5

Previous studies have shown a decrease in the phosphorylation of p70s6K, an mTOR substrate, in response to synthetic CB1/2 agonist54 or THC55 in cancer cells linked to autophagy pathways. STAT5 is also crucial in the regulation of cell fate, and its activation is key in angiogenesis.56 The reduction in the levels of phosphorylated p70s6K and STAT5 in human endothelial cells in response to CBD in the present study may represent the intracellular signalling mechanisms underpinning the anti-angiogenic effects of CBD reported by Solinas et al.57 in human umbilical vein endothelial cells.

Given the variability of the responses seen to CBD, post hoc analysis of patient medical notes was undertaken. We found that CBD-induced...
CBD Induced vasorelaxation of human arteries

577

Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234–246.

Izzo AA, Bellesi F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant can-
nabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515–527.

Zuardi AW. Cannabidiol from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2001;23:271–280.

Iuvone T, Esposito G, De Filippis D, Scuderi C, Stardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65–75.

Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biol Med 2011;51:1054–1061.

Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Kato G, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J Neuroinflammation 2011;8:B5.

El Remessy AB, Al-Shabrawy M, Khalifa Y, Tsai N-T, Caldwell RB, Liou GL. Neuropro-
tective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235–244.

Wynne SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol 2010;160:1214–1242.

Hayakawa K, Mishima K, Irie K, Hazezawa M, Mishima S, Fujikura M, Ohto K, Egashira N, Katsurabayashi S, Takasaka K, Iwaski K, Fujisawa M. Cannabidiol prevents a post-
ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008;55:1280–1286.

Hayakawa K, Mishima K, Nozako M, Ogata A, Hazezawa M, Liu AX, Fujikura M, Abe K, Hasebe N, Egashira N, Iwaski K, Fujisawa M. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the develop-
ment of tolerance. Neuropharmacology 2007;52:1079–1087.

Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwaski K, Fujisawa M. Cannabidiol prevents cerebral infarction via a serotoninergic 5-hydroxytryptamine1A receptor-
dependent mechanism. Stroke 2005;36:1077–1083.

Hayakawa K, Mishima K, Nozako M, Hazezawa M, Irie K, Fujikura M, Ohto K, Abe K, Hasebe N, Egashira N, Iwaski K, Fujisawa M. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-
inhibiting mechanism. J Neurochem 2007;102:1488–1496.

Jari Z, Wagner JA, Varga KR, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Pacher P. Cannabinoid-attenuates high glucose-induced endothelial cell inflammatory signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2008;52:H610–H619.

Rajesh M, Mukhopadhyay P, Batkai S, Hazezawa M, Laiquddin L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Cell Physiol 2009;293:H610–H619.

Rizzi-Valdenpes L, Martinez-Orrego JA, Benito C, Millan A, Talon RM, Romero J. Cannabidiol reduces iNOS and suppresses the expression of monocyte chemoattractant protein-1 in human aortic endothelial cells. Br J Pharmacol 2003;140:420–430.

Sorrentino F, Di Marzo V. The heart of the matter: the endocannabinoid system in cardio-
vascular function and dysfunction. Trends Pharmacol Sci 2012;33:331–340.

Schubart CD, Sommer IE, van Gassel WA, Goetgebuer RL, Kahn RS, Boksa MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Res 2011;130:216–221.

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant canna-
nabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabinirvin. Br J Pharmacol 2000;133:199–215.

Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol 2014;171:1361–1378.

Montemurco F, Di Mauro V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331–340.

Conflict of interest: none declared.

References

1. Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol 2014;171:1361–1378.
2. Montemurco F, Di Mauro V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331–340.
3. Schubart CD, Sommer IE, van Gassel WA, Goetgebuer RL, Kahn RS, Boksa MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Res 2011;130:216–221.
4. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant canna-
nabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabinirvin. Br J Pharmacol 2000;133:199–215.

CBD Induced vasorelaxation of human arteries

1. Stanley C, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Pharmacol 2013;170:313–322.
2. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234–246.
3. Izzo AA, Bellesi F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant can-
nabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515–527.
4. Zuardi AW. Cannabidiol from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2001;23:271–280.
5. Iuvone T, Esposito G, De Filippis D, Scuderi C, Stardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65–75.
6. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biol Med 2011;51:1054–1061.
7. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Kato G, Egashira N, Katsurabayashi S, Takasaka K, Iwaski K, Fujisawa M. Cannabidiol prevents a post-
ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008;55:1280–1286.
8. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazezawa M, Liu AX, Fujikura M, Abe K, Hasebe N, Egashira N, Iwaski K, Fujisawa M. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the develop-
ment of tolerance. Neuropharmacology 2007;52:1079–1087.
9. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwaski K, Fujisawa M. Cannabidiol prevents cerebral infarction via a serotoninergic 5-hydroxytryptamine1A receptor-
dependent mechanism. Stroke 2005;36:1077–1083.
10. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biol Med 2011;51:1054–1061.
11. Rajesh M, Mukhopadhyay P, Batkai S, Hazezawa M, Laiquddin L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Cell Physiol 2009;293:H610–H619.
12. Rajesh M, Mukhopadhyay P, Batkai S, Hazezawa M, Laiquddin L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Cell Physiol 2009;293:H610–H619.
13. Rizzi-Valdenpes L, Martinez-Orrego JA, Benito C, Millan A, Talon RM, Romero J. Cannabidiol reduces iNOS and suppresses the expression of monocyte chemoattractant protein-1 in human aortic endothelial cells. Br J Pharmacol 2003;140:420–430.
14. Montemurco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331–340.
15. Schubart CD, Sommer IE, van Gassel WA, Goetgebuer RL, Kahn RS, Boksa MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Res 2011;130:216–221.
16. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant canna-
nabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabinirvin. Br J Pharmacol 2000;133:199–215.
31. Wang J, Okamoto Y, Tsuibo K, Ueda N. The stimulatory effect of phosphatidylethanolamine on N-acetyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Neuropharmacology 2008;54:8–15.
32. Sugura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabinimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res 1998;243:838–843.
33. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P. CB2 receptor-stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007;293:H2210–H2218.
34. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008;153:347–357.
35. Liu J, Gao B, Mrshali S, Fanyal AJ, Khandkar AD, Makryannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000;346(Pt 3):835–840.
36. Showalter VM, Compton DR, Martin BR, Aboud ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996:278:989–999.
37. Bisogno T, Hanus L, De Petrocellis L, Tchilbion B, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabinoids and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845–852.
38. Stanley C, Manning G, O’Sullivan S. Cannabinoid induced vasoorelaxation of human mesenteric arteries. Proceeding of the British Pharmacological Society Meeting 2010. http://bps-conference-services.net/resources/344/2336/pdf/BPSWINTER10_0158.pdf.
39. Stanley CP, O’Sullivan SE. Cyclooxygenase metabolism mediates vasoexcitation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res 2014;81:74–82.
40. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997:100:1538–1546.
41. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479–1494.
42. Yamada T, Ueda T, Shibata Y, Ilegama Y, Saito M, Ishida Y, Uogwa S, Kohn K, Shimada S. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 2010;76:509 e501–507.
43. Costa B, Giagnoni G, Francke C, Trovato AE, Colleoni M. Vanillinoid TRPV1 receptor mediates the antihypersensitive effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004;143:247–250.
44. Costa B, Trovato AE, Cornelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;556:75–83.
45. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-tetrahydrocannabinol and cannabinoid activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002;22:4720–4727.
46. Edvinsson L, Ahnstedt H, Larsen R, Sheykzhade M. Differential localization and characterization of functional cannabinin gene-related peptide receptors in human subcutaneous arteries. Acta Physiol 2014;210:811–822.
47. O’Sullivan SE, Kendall DA, Randall MD. Further characterization of the time-dependent vascular effects of Δ9 tetrahydrocannabinol. J Pharmacol Exp Ther 2006;317:438–438.
48. O’Sullivan SE, Kendall DA, Randall MD. The effects of Δ9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 2005;145:514–526.
49. Rock EM, Bolognini D, Limebeer CL, Cassio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychoactive component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of S-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012;165:2620–2634.
50. Campos AC, Guimarães FS. Involvement of SHT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psycho-pharmacol 2008;199:223–230.
51. McCollum C, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007;321:930–937.
52. Mo FM, Offerter L, Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 2004;489:21–27.
53. Mukhopadhyay P, Rajesh M, Horvath B, Batkai S, Park O, Tanchan G, Gao RY, Patel V, Wink DA, Liaudet L, Hasko G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Rad Biol Med 2011;50:1368–1381.
54. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D’Alessandro A, Zolla L, Palmieri M. Cannabinoids inhibit enterochromaffin-like cells of AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis 2013;4:e664.
55. Salazar M, Carracedo A, Salanueva IG, Hernandez-Tiedra S, Lorente M, Egia A, Vazquez P, Blazquez C, Torres S, Garcia S, Nowak J, Fimia GM, Piczentini M, Cescioni F, PandoPF, Gonzalez-Feria L, Iovanna JL, Guzman M, Boya P, Velasco G. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glia cells. J Clin Invest 2009;119:1359–1372.
56. Yang X, Meyer K, Friedl M. STAT3 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J Biol Chem 2013;288:21184–21196.
57. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartoloni D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol 2012;167:1218–1231.
58. Novella S, Dantas AP, Segara G, Medina P. Hermengildo C. Vascular aging in women: is estrogen the fountain of youth? Front Physiol 2012;3:165.
59. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, Hubbard JR. Expression of cannabinoid receptors and their gene transcripts in human blood cells. Prog Neuro-psychopharmacol Biol Psychiatry 1999;23:1063–1077.
60. Lobato NS, Filgueira FP, Prakash R, Giachini FR, Arul E, Carvalho MH, Webb RC, Tostes RC, Fortes ZB. Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One 2013;8:e63449.
61. Steffens S, Pacher P. Targeting cannabinoid receptor CB2(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 2012;167:313–322.
62. Guarini G, Ohanyan VA, Knetz JG, DelloStritto DJ, Thoppil RJ, Thodeti CK, Meszaregs JG, Damron DS, Bratn IN. Disruption of TRPV1-mediated coupling of coronary blood flow to cardiac metabolism in diabetic mice: role of nitric oxide and BK channels. Am J Physiol Heart Circ Physiol 2012;303:H216–H223.
63. Pizacano-Juarez G, Romero-Suarez S, Nieto-Pousadas A, Llorente I, Jara-Oseguera A, Briggs M, McIntosh TJ, Simon SA, Ladrón-de-Guevara E, Islas LD, Rosenbaum T. Identification of a binding motif in the 55 helix that confers cholesterol sensitivity to the TRPV1 ion channel. J Biol Chem 2011;286:24966–24976.